Body Plethysmography (Body Box)
Body Plethysmography (Body Box) is an advanced, highly accurate pulmonary function test performed inside an airtight, telephone booth-sized transparent chamber called a plethysmograph, used to measure lung volumes and airway resistance that cannot be determined by standard spirometry alone. During the test, the patient sits inside the sealed chamber and breathes through a mouthpiece while the door is closed. At a specific point, a shutter briefly blocks airflow and the patient is asked to pant gently against the closed shutter. The pressure changes inside the box and at the mouth are measured simultaneously by sensitive sensors, and using Boyle's Law — which states that pressure and volume of a gas are inversely related at constant temperature — the device calculates precise measurements of lung volumes and airway mechanics. The key measurements obtained include Total Lung Capacity (TLC), which is the total volume of air the lungs can hold at maximum inhalation; Residual Volume (RV), which is the amount of air remaining in the lungs after a complete forced exhalation that cannot be expelled; Functional Residual Capacity (FRC), which is the volume of air remaining in the lungs at the end of a normal passive exhalation; and Specific Airway Resistance (sRaw) and Airway Resistance (Raw), which measure the resistance to airflow within the airways, useful for detecting early or subtle airway obstruction. Clinically, body plethysmography is used to confirm and characterize obstructive lung diseases such as asthma and COPD by demonstrating air trapping and hyperinflation through elevated RV and TLC; to diagnose restrictive lung conditions such as pulmonary fibrosis or chest wall disorders by showing a reduced TLC; to differentiate between true restriction and pseudo-restriction that may appear on spirometry alone; to evaluate patients before lung surgery to assess remaining lung function; and to monitor disease progression and response to treatment over time. Body plethysmography is considered the gold standard for measuring absolute lung volumes and is superior to other lung volume techniques such as gas dilution methods, particularly in patients with severe airflow obstruction or air trapping, where gas dilution tests tend to underestimate lung volumes. When combined with spirometry and FENO, it provides the most complete and detailed assessment of a patient's overall respiratory function.
FENO (Fractional Exhaled Nitric Oxide) Test
Fractional Exhaled Nitric Oxide (FENO) is a non-invasive, real-time diagnostic breath test used to measure the concentration of nitric oxide (NO) gas in a patient's exhaled breath, reported in parts per billion (ppb). Nitric oxide is naturally produced by the epithelial cells lining the airways in response to inflammatory cytokines, particularly those associated with eosinophilic (allergic-type) inflammation. When the airways are inflamed — as seen in conditions like allergic asthma or eosinophilic bronchitis — nitric oxide production increases significantly, making elevated FENO levels a reliable biomarker of underlying airway inflammation. The test is performed by having the patient inhale deeply to full lung capacity and then exhale slowly and steadily through a handheld or tabletop device at a controlled flow rate of approximately 50 mL/second. The device analyzes the exhaled breath in real time and delivers an immediate result, typically within seconds to minutes. No special preparation, bronchodilator, or invasive procedure is required, making it well-tolerated by both adults and children as young as 4 to 5 years of age. Clinically, FENO serves multiple important purposes. It aids in confirming an eosinophilic component in patients presenting with respiratory symptoms suggestive of asthma, helps differentiate asthma phenotypes (eosinophilic vs. non-eosinophilic), guides the initiation or adjustment of inhaled corticosteroid (ICS) therapy, monitors a patient's response to anti-inflammatory treatment over time, and can detect non-adherence to prescribed corticosteroid inhalers, as FENO levels tend to rise when steroid use is discontinued. According to American Thoracic Society (ATS) guidelines, a FENO level below 25 ppb in adults (below 20 ppb in children) suggests that eosinophilic inflammation is unlikely, a level between 25 and 50 ppb is considered intermediate and requires interpretation within the broader clinical context, and a level above 50 ppb in adults (above 35 ppb in children) strongly indicates significant eosinophilic airway inflammation. However, FENO should never be used in isolation — it is most valuable when interpreted alongside a patient's clinical history, symptoms, spirometry results, and response to therapy, as various factors such as smoking, recent corticosteroid use, or active respiratory infections can falsely lower FENO readings, while allergic rhinitis or atopic dermatitis can elevate them independent of asthma.
Modified Cardiopulmonary Exercise Test (M.CPET)
Maximal Cardiopulmonary Exercise Testing (M.CPET) is a sophisticated, non-invasive diagnostic test that simultaneously evaluates the integrated response of the cardiovascular, pulmonary, metabolic, and musculoskeletal systems during progressively increasing levels of physical exercise, taken to the point of maximum exertion or symptom limitation. It is considered the gold standard for objectively assessing exercise capacity and identifying the precise cause of unexplained exertional symptoms such as breathlessness, fatigue, or reduced exercise tolerance. During the test, the patient exercises on a treadmill or stationary cycle ergometer while wearing a mouthpiece or face mask connected to a metabolic cart that continuously analyzes expired gases breath by breath. Simultaneously, a 12-lead ECG monitors cardiac rhythm and electrical activity, blood pressure is measured at regular intervals, and oxygen saturation is tracked via pulse oximetry. The exercise workload is increased incrementally in a standardized ramp or step protocol until the patient reaches their maximum effort, is unable to continue due to symptoms, or a safety endpoint is reached requiring test termination. The key measurements obtained include Maximal Oxygen Uptake (VO2 max), which is the highest rate at which the body can consume oxygen during maximum exercise and is the single most important indicator of cardiorespiratory fitness and functional capacity; Anaerobic Threshold (AT) or Ventilatory Threshold, which is the point during exercise at which the body shifts from aerobic to anaerobic metabolism and lactic acid begins to accumulate, reflecting the sustainable level of exercise; VE/VCO2 slope, which measures the efficiency of ventilation relative to carbon dioxide output and is a powerful prognostic marker particularly in heart failure and pulmonary hypertension; Oxygen Pulse (VO2/HR), which reflects stroke volume and cardiac efficiency during exercise; Breathing Reserve, which indicates how much ventilatory capacity remains at peak exercise and helps distinguish cardiac from pulmonary limitation; and Heart Rate Response and Recovery, which assess chronotropic competence and autonomic function. Clinically, M.CPET is used to investigate unexplained dyspnea or exercise intolerance when standard resting tests such as spirometry, echocardiography, or ECG fail to identify a cause; to differentiate between cardiac, pulmonary, peripheral vascular, or deconditioning-related causes of exercise limitation; to evaluate and risk-stratify patients with heart failure, pulmonary arterial hypertension, COPD, or interstitial lung disease; to assess functional capacity before major surgical procedures including lung resection, cardiac surgery, or organ transplantation; to guide exercise prescription in cardiac and pulmonary rehabilitation programs; to monitor disease progression and response to medical therapy over time; and to evaluate professional or competitive athletes for performance optimization and fitness assessment. Interpretation of M.CPET results requires integrating multiple variables together rather than viewing any single measurement in isolation. A cardiovascular limitation pattern typically shows a reduced VO2 max, early anaerobic threshold, reduced oxygen pulse, and adequate breathing reserve. A pulmonary limitation pattern shows a reduced breathing reserve, abnormal gas exchange, and oxygen desaturation during exercise with a relatively preserved oxygen pulse. Deconditioning presents with a reduced VO2 max and early anaerobic threshold but normal breathing reserve and oxygen pulse. Each pattern guides the clinician toward the most likely underlying cause and the most appropriate next steps in management. M.CPET is a highly specialized test requiring experienced personnel, careful patient selection, and strict safety protocols given that it pushes the patient to maximum physiological limits. When interpreted by trained specialists alongside clinical history, resting pulmonary function tests, and cardiac investigations, it provides an unparalleled and comprehensive window into the functional reserve of the entire cardiorespiratory system.
Polysomnography (sleep study)
Sleep Apnea is a common but serious sleep disorder characterized by repeated episodes of partial or complete cessation of breathing during sleep, lasting at least 10 seconds and occurring multiple times throughout the night, leading to fragmented sleep, recurrent drops in blood oxygen levels, and significant strain on the cardiovascular and metabolic systems. There are three main types of sleep apnea. Obstructive Sleep Apnea (OSA) is the most prevalent form, caused by the physical collapse or blockage of the upper airway due to relaxation of the throat muscles during sleep, resulting in snoring, choking, or gasping episodes. Central Sleep Apnea (CSA) occurs when the brain fails to send proper signals to the muscles that control breathing, representing a neurological rather than anatomical problem. Mixed or Complex Sleep Apnea is a combination of both obstructive and central components occurring in the same individual. Common symptoms include loud and persistent snoring, witnessed breathing pauses during sleep, abrupt awakenings accompanied by choking or gasping, excessive daytime sleepiness and fatigue regardless of the duration of sleep, morning headaches, difficulty concentrating, irritability, and poor memory. Many patients remain undiagnosed for years as the most disruptive symptoms occur during sleep and are often noticed first by a bed partner rather than the patient themselves. Clinically, sleep apnea is diagnosed through a sleep study known as Polysomnography (PSG), conducted either in a sleep laboratory or via a home sleep apnea test (HSAT). The key diagnostic parameter is the Apnea-Hypopnea Index (AHI), which measures the average number of apnea and hypopnea events per hour of sleep. An AHI of 5 to 14 indicates mild sleep apnea, 15 to 30 indicates moderate sleep apnea, and above 30 indicates severe sleep apnea requiring prompt treatment. If left untreated, sleep apnea significantly increases the risk of hypertension, coronary artery disease, stroke, cardiac arrhythmias, type 2 diabetes, metabolic syndrome, pulmonary hypertension, and road traffic accidents due to impaired alertness. Treatment options include Continuous Positive Airway Pressure (CPAP) therapy, which is the gold standard and works by delivering a constant stream of pressurized air to keep the airway open during sleep; BiPAP or Auto-PAP devices for patients who cannot tolerate standard CPAP; oral mandibular advancement devices for mild to moderate OSA; positional therapy; surgical interventions such as uvulopalatopharyngoplasty (UPPP) in selected cases; and lifestyle modifications including weight loss, avoidance of alcohol and sedatives, and smoking cessation, all of which play an important supporting role in overall management.
Spirometry
Spirometry is a common, non-invasive pulmonary function test that measures the amount (volume) and speed (flow) of air a person can inhale and exhale, used to assess lung function and diagnose or monitor respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other obstructive or restrictive lung disorders. During the test, the patient is asked to take the deepest breath possible and then exhale as forcefully and completely as possible into a mouthpiece connected to a spirometer device. This is repeated typically three times to ensure accurate and reproducible results. The key measurements obtained include Forced Vital Capacity (FVC), which is the total volume of air exhaled after a maximum inhalation; Forced Expiratory Volume in one second (FEV1), which is the volume of air exhaled in the first second of the forced breath; and the FEV1/FVC ratio, which compares these two values and is the most critical parameter for identifying the presence and type of lung dysfunction. Clinically, spirometry is used to detect airflow obstruction, as seen in asthma and COPD, where the FEV1/FVC ratio falls below 0.70 (70%), indicating that air is being trapped or cannot be expelled normally. It is also used to identify restrictive lung patterns, where both FVC and FEV1 are reduced but the ratio remains normal or elevated, as seen in conditions like pulmonary fibrosis or chest wall deformities. Additionally, spirometry is used to assess the severity of lung disease, monitor disease progression over time, evaluate a patient's response to bronchodilator therapy (pre and post bronchodilator testing), screen high-risk individuals such as long-term smokers, and assess fitness before surgery. Interpretation of spirometry results is guided by predicted normal values based on the patient's age, height, sex, and ethnicity. A result is considered abnormal when key values fall below 80% of the predicted normal. An obstructive pattern shows a reduced FEV1/FVC ratio with a normal or reduced FVC, while a restrictive pattern shows a reduced FVC with a preserved or elevated ratio. A mixed pattern can also occur when both obstruction and restriction are present simultaneously. Spirometry is widely regarded as the gold standard for diagnosing and staging obstructive lung diseases, particularly COPD, and when combined with clinical assessment and other tests such as FENO or chest imaging, it provides a comprehensive picture of a patient's respiratory health.
Tele-Cardiopulmonary Monitoring (TCM)
Tele-Cardiopulmonary Monitoring (TCM) is a supervised, non-invasive exercise-based assessment performed on a stationary cycle ergometer, designed to continuously monitor and evaluate a patient's cardiopulmonary response during controlled physical activity in a clinical setting. Unlike maximal exercise testing, TCM is typically conducted at submaximal workloads, making it accessible and safe for a broader range of patients including the elderly, deconditioned individuals, and those with chronic respiratory or cardiac conditions. During the test, the patient pedals on a recumbent or upright stationary cycle at a set resistance or progressively increasing workload while a trained clinician remotely monitors real-time physiological data through connected monitoring equipment. Key parameters tracked throughout the session include heart rate, oxygen saturation (SpO2), respiratory rate, blood pressure, and perceived exertion, allowing the clinician to assess how well the cardiovascular and pulmonary systems respond to and recover from physical stress. Clinically, TCM is used to evaluate functional exercise capacity in patients with chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, heart failure, or post-COVID respiratory impairment; to guide and individualize pulmonary and cardiac rehabilitation programs; to monitor patient progress and response to therapy over repeated sessions; to safely assess exercise tolerance in patients who may not be suitable for maximal testing; and to identify exercise-induced oxygen desaturation or abnormal cardiac responses that may require further investigation. As part of an integrated pulmonary care approach, TCM bridges the gap between resting pulmonary function tests and full maximal cardiopulmonary exercise testing, offering a practical, patient-friendly, and clinically meaningful evaluation of real-world functional capacity and exercise safety.